Systemic light-chain (AL) amyloidosis is a multi-system disease and therefore can implicate a large variety of organ systems. COVID-19 is not only a systemic disease but may also cause cytokine storm and hence present a clinical threat to amyloidosis patients. Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, outlines the challenges associated with the management of patients with AL amyloidosis during the COVID-19 pandemic. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).